Afficher la notice abrégée

Nanoparticles based on natural, engineered or synthetic proteins and polypeptides for drug delivery applications

dc.rights.licenseopen
hal.structure.identifierLaboratoire de Chimie des Polymères Organiques [LCPO]
hal.structure.identifierTeam 3 LCPO : Polymer Self-Assembly & Life Sciences
dc.contributor.authorGEORGILIS, Evangelos
hal.structure.identifierEindhoven University of Technology [Eindhoven] [TU/e]
dc.contributor.authorABDELGHANI, Mona
hal.structure.identifierEindhoven University of Technology [Eindhoven] [TU/e]
dc.contributor.authorPILLE, Jan
hal.structure.identifierLaboratoire de Chimie des Polymères Organiques [LCPO]
hal.structure.identifierTeam 3 LCPO : Polymer Self-Assembly & Life Sciences
dc.contributor.authorAYDINLIOGLU, Esra
hal.structure.identifierEindhoven University of Technology [Eindhoven] [TU/e]
dc.contributor.authorVAN HEST, Jan C.M.
hal.structure.identifierLaboratoire de Chimie des Polymères Organiques [LCPO]
hal.structure.identifierTeam 3 LCPO : Polymer Self-Assembly & Life Sciences
dc.contributor.authorLECOMMANDOUX, Sebastien
hal.structure.identifierLaboratoire de Chimie des Polymères Organiques [LCPO]
hal.structure.identifierTeam 3 LCPO : Polymer Self-Assembly & Life Sciences
dc.contributor.authorGARANGER, Elisabeth
IDREF: 089451740
dc.date.accessioned2020
dc.date.available2020
dc.date.issued2020
dc.identifier.issn0378-5173
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/19670
dc.description.abstractEnMedicine formulations at the nanoscale, referred to as nanomedicines, have managed to overcome key challenges encountered during the development of new medical treatments and entered clinical practice, but considerable improvement in terms of local efficacy and reduced toxicity still need to be achieved. Currently, the fourth-generation of nanomedicines is being developed, employing biocompatible nanocarriers that are targeted, multifunctional, and stimuli-responsive. Proteins and polypeptides can fit the standards of an efficient nanovector because of their biodegradability, intrinsic bioactivity, chemical reactivity, stimuli-responsiveness, and ability to participate in complex supramolecular assemblies. These biomacromolecules can be obtained from natural resources, produced in heterologous hosts, or chemically synthesized, allowing for different designs to access suitable carriers for a variety of drugs. To enhance targeting or therapeutic functionality, additional chemical modifications can be applied. This review demonstrates the potential of polypeptide and protein materials for the design of drug delivery nanocarriers with a special focus on their preclinical evaluation in vitro and in vivo.
dc.description.sponsorshipDéveloppement de polymersomes avec possibilité de suivi par imagerie et activation à distance pour la libération de composés d’intérêt thérapeutique dans des tissus profonds - ANR-14-CE08-0013
dc.description.sponsorshipDéveloppement de squelettes polypeptidiques recombinants pour la synthèse de glycoconjugués multivalents parfaitement définis - ANR-15-CE07-0002
dc.language.isoen
dc.publisherElsevier
dc.subject.enPolypeptides
dc.subject.enSynthetic proteins
dc.subject.enNanomedecine
dc.subject.enDrug delivery
dc.subject.enNanocarriers
dc.subject.enNanoparticles/administration & dosage
dc.title.enNanoparticles based on natural, engineered or synthetic proteins and polypeptides for drug delivery applications
dc.typeArticle de revue
dc.identifier.doi10.1016/j.ijpharm.2020.119537
dc.subject.halChimie/Polymères
dc.subject.halPhysique [physics]/Matière Condensée [cond-mat]/Matière Molle [cond-mat.soft]
dc.subject.halSciences du Vivant [q-bio]/Sciences pharmaceutiques
dc.subject.halSciences du Vivant [q-bio]/Biotechnologies
dc.subject.halSciences du Vivant [q-bio]/Ingénierie biomédicale/Biomatériaux
dc.description.sponsorshipEuropeNanomedicine: an integrative approach
bordeaux.journalInternational Journal of Pharmaceutics
bordeaux.page119537
bordeaux.volume586
bordeaux.hal.laboratoriesLaboratoire de Chimie des Polymères Organiques (LCPO) - UMR 5629*
bordeaux.institutionBordeaux INP
bordeaux.institutionUniversité de Bordeaux
bordeaux.peerReviewedoui
hal.identifierhal-02863342
hal.version1
hal.origin.linkhttps://hal.archives-ouvertes.fr//hal-02863342v1
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=International%20Journal%20of%20Pharmaceutics&rft.date=2020&rft.volume=586&rft.spage=119537&rft.epage=119537&rft.eissn=0378-5173&rft.issn=0378-5173&rft.au=GEORGILIS,%20Evangelos&ABDELGHANI,%20Mona&PILLE,%20Jan&AYDINLIOGLU,%20Esra&VAN%20HEST,%20Jan%20C.M.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée